Post Wed Nov 23, 2022 6:26 pm

2022-Amaria et al-Nature

"Neoadjuvant relatlimab and nivolumab in resectable melanoma"
Rodabe N Amaria, Michael Postow, Elizabeth M Burton, Michael T Tezlaff, Merrick I Ross, Carlos Torres-Cabala, Isabella C Glitza, Fei Duan, Denái R Milton, Klaus Busam, Lauren Simpson, Jennifer L McQuade, Michael K Wong, Jeffrey E Gershenwald, Jeffrey E Lee, Ryan P Goepfert, Emily Z Keung, Sarah B Fisher, Allison Betof-Warner, Alexander N Shoushtari, Margaret Callahan, Daniel Coit Edmund K Bartlett, Danielle Bello, Parisa Momtaz, Courtney Nicholas, Aidi Gu, Xuejun Zhang, Brinda Rao Korivi, Madhavi Patnana, Sapna P Patel, Adi Diab, Anthony Lucci, Victor G Prieto, Michael A Davies, James P Allison, Padmanee Sharma, Jennifer A Wargo, Charlotte Ariyan, Hussein A Tawbi
Nature. 2022, 611, 155-160
https://doi.org/10.1038/s41586-022-05368-8

- "Data availability Data supporting the findings of this study have been provided to Nature through direct deposition."
- I honestly have no idea what this means; the Reporting Summary says "Full data to be provided upon request, there are no restrictions"